T. Rowe Price Investment Management
SNDX icon

T. Rowe Price Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

T. Rowe Price Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85,511
Closed -$1.65M – 670
2024
Q3 		$1.65M Sell
85,511
-198,316
-70% -$4.1M ﹤0.01% 591
2024
Q2 		$5.83M Sell
283,827
-2,175,408
-88% -$45.5M ﹤0.01% 565
2024
Q1 		$58.5M Sell
2,459,235
-252,018
-9% -$5.62M 0.04% 365
2023
Q4 		$58.6M Buy
2,711,253
+1,644,705
+154% +$25.3M 0.04% 369
2023
Q3 		$15.5M Hold
1,066,548
– – 0.01% 500
2023
Q2 		$22.3M Buy
1,066,548
+65,833
+7% +$1.37M 0.02% 464
2023
Q1 		$21.1M Sell
1,000,715
-2,171
-0.2% -$54K 0.02% 465
2022
Q4 		$25.5M Buy
1,002,886
+79,660
+9% +$1.86M 0.02% 435
2022
Q3 		$22.2M Buy
+923,226
New +$20.7M 0.02% 440

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Investment Management's SNDX Position: Q4 2024 in Review

T. Rowe Price Investment Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 85,511 shares — an estimated $1.65M sold.

T. Rowe Price Investment Management first reported a position in SNDX in Q3 2022 and held it in 9 quarters. The position peaked at $58.6M in Q4 2023. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • T. Rowe Price Investment Management reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 85,511 Syndax Pharmaceuticals shares in Q4 2024, an estimated $1.65M.
  • T. Rowe Price Investment Management first reported a position in Syndax Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • T. Rowe Price Investment Management's Syndax Pharmaceuticals position peaked at $58.6M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.